GRI Bio, Inc. (GRI) 股票分析

公司概述

GRI Bio, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery, development, and commercialization of therapeutic interventions targeting inflammatory, fibrotic, and autoimmune disorders within the United States market. The company functions specifically within the healthcare sector and the biotechnology industry, positioning itself to address significant unmet medical needs in chronic disease management. As of the latest available data, the firm maintains a market capitalization of $3.41 million, employs a workforce of three individuals, and reports N/A for its trailing twelve-month revenue figures. These valuation metrics indicate that GRI Bio is a micro-cap enterprise with extremely limited scale, operating without current revenue generation and relying heavily on external capital or internal reserves to fund its clinical-stage pipeline.

财务健康

The company reports a net income of $-11,956,000 and an EBITDA of $-11,973,000 for the trailing twelve-month period, while revenue is listed as N/A. The substantial gap between the reported net income and EBITDA, which are nearly identical in their negative magnitude, reveals a cost structure where interest expenses or other non-operating costs are negligible relative to the massive operating losses inherent in the early-stage biotechnology model. Free cash flow stands at $-5,468,625, indicating that the company is currently burning cash at a rapid pace, which necessitates continuous fundraising or asset liquidation to maintain financial solvency. Margins across the board are reported at 0.0%, with gross margin, operating margin, and profit margin all showing zero values, a typical characteristic for pre-revenue companies where no sales have occurred to generate gross profit. The balance sheet shows a cash position of $8.23 million against a debt load of only $71,000, resulting in a debt-to-equity ratio of 1.18, suggesting a leveraged position relative to equity but with minimal absolute debt exposure. The current ratio is 3.25, which indicates strong short-term liquidity relative to current liabilities, providing a buffer to cover obligations despite the negative earnings. Return on Equity is -238.2% and Return on Assets is -103.9%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently in terms of generating positive returns, a common but risky phase for clinical-stage firms attempting to transition from research to commercial viability.

估值评估

The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is listed as -0.29, a negative figure that implies the market is pricing in significant future losses rather than expecting immediate profitability. The price-to-book ratio is 0.20, indicating that the stock trades at a significant discount to its book value, which often reflects the market's skepticism regarding the ability of the clinical pipeline to generate future cash flows. The price-to-sales ratio is N/A, and the EV/EBITDA stands at 0.40, suggesting a valuation based on enterprise value relative to earnings before interest, taxes, depreciation, and amortization that is depressed by the company's current losses. The 52-week high is $80.36 and the 52-week low is $2.10, meaning the current market price sits significantly below the historical peak, reflecting a substantial correction or lack of institutional interest over the past year. The beta value is -1.24, a highly unusual negative figure that suggests the stock's price volatility moves inversely to the broader market, presenting unique risks for portfolio diversification strategies.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both N/A, as the company lacks the historical financial data required to calculate growth rates for a firm with N/A revenue. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm reinvests all available resources, however limited, into research and development rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of current profitability and revenue streams, relying entirely on the potential future success of its lead product candidate, GRI-0621, to alter its financial trajectory in the coming years.